Elaine McFarlane

574 total citations
19 papers, 388 citations indexed

About

Elaine McFarlane is a scholar working on Hepatology, Epidemiology and Pathology and Forensic Medicine. According to data from OpenAlex, Elaine McFarlane has authored 19 papers receiving a total of 388 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hepatology, 11 papers in Epidemiology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Elaine McFarlane's work include Liver Diseases and Immunity (13 papers), Liver Disease Diagnosis and Treatment (11 papers) and Systemic Lupus Erythematosus Research (3 papers). Elaine McFarlane is often cited by papers focused on Liver Diseases and Immunity (13 papers), Liver Disease Diagnosis and Treatment (11 papers) and Systemic Lupus Erythematosus Research (3 papers). Elaine McFarlane collaborates with scholars based in United Kingdom, Belgium and Italy. Elaine McFarlane's co-authors include Dermot Gleeson, Asha Dubé, Mohammed Karajeh, Barbara Hoeroldt, Pandurangan Basumani, Michael J. Campbell, James Underwood, David Elphick, Lynne Lennard and Sarah Schneider and has published in prestigious journals such as Gastroenterology, Hepatology and Gut.

In The Last Decade

Elaine McFarlane

15 papers receiving 378 citations

Peers

Elaine McFarlane
A. D’Arienzo Italy
G. Cesaro Italy
I. Carderi Italy
D. Caroli Italy
M Orsini Italy
Ryoichi Narita Japan
Enrico O. Souto United States
E Tavani Italy
Sulleman Moreea United Kingdom
Pilar Cubiles Sánchez-Pobre Spain
A. D’Arienzo Italy
Elaine McFarlane
Citations per year, relative to Elaine McFarlane Elaine McFarlane (= 1×) peers A. D’Arienzo

Countries citing papers authored by Elaine McFarlane

Since Specialization
Citations

This map shows the geographic impact of Elaine McFarlane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elaine McFarlane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elaine McFarlane more than expected).

Fields of papers citing papers by Elaine McFarlane

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elaine McFarlane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elaine McFarlane. The network helps show where Elaine McFarlane may publish in the future.

Co-authorship network of co-authors of Elaine McFarlane

This figure shows the co-authorship network connecting the top 25 collaborators of Elaine McFarlane. A scholar is included among the top collaborators of Elaine McFarlane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elaine McFarlane. Elaine McFarlane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Abdel‐Rahman, Omar, et al.. (2025). Advances in cancer therapy require urgent changes to the oncology workforce. Canadian Medical Association Journal. 197(21). E590–E596.
2.
Dixon, Selena, L. Harrison, Barbara Hoeroldt, Elaine McFarlane, & Dermot Gleeson. (2019). PTU-008 Diabetes mellitus in patients with autoimmune hepatitis (AIH): at diagnosis and following prednisolone treatment. A115.1–A115. 1 indexed citations
3.
4.
Barclay, Matthew, et al.. (2016). Increased Long-Term Cancer Risk in Autoimmune Hepatitis: Relation to Immunosuppressive Drug Treatment. Journal of Hepatology. 64(2). S431–S432. 2 indexed citations
5.
6.
Hoeroldt, Barbara, Asha Dubé, Elaine McFarlane, et al.. (2015). Long-Term Prognostic Significance of Persisting Histological Activity Despite Biochemical Remission in Autoimmune Hepatitis. The American Journal of Gastroenterology. 110(7). 993–999. 75 indexed citations
7.
McFarlane, Elaine, et al.. (2014). PTU-136 Does A Normal Igg Indicate Histological Remission In Autoimmune Hepatitis (aih)?. Gut. 63(Suppl 1). A98.2–A98. 1 indexed citations
8.
McFarlane, Elaine, et al.. (2013). PTU-085 Decompensated Alcoholic Liver Disease (ALD): High Long-Term Mortality Despite Initial Survival. Gut. 62(Suppl 1). A81.1–A81. 1 indexed citations
9.
Anderson, Rory, et al.. (2012). Clinical significance of azathioprine metabolites for the maintenance of remission in autoimmune hepatitis. Hepatology. 56(4). 1401–1408. 54 indexed citations
10.
11.
12.
Dube, Anuradha, et al.. (2011). 1290 TREATMENT OF AUTOIMMUNE HEPATITIS: WHAT IS THE OPTIMAL ENDPOINT ON FOLLOW-UP BIOPSY?. Journal of Hepatology. 54. S508–S509. 1 indexed citations
13.
Hoeroldt, Barbara, et al.. (2011). Treatment of autoimmune hepatitis: what is the optimal end point on follow-up biopsy?. Gut. 60(Suppl 1). A229.1–A229. 2 indexed citations
14.
Hoeroldt, Barbara, Elaine McFarlane, Asha Dubé, et al.. (2011). Long-term Outcomes of Patients With Autoimmune Hepatitis Managed at a Nontransplant Center. Gastroenterology. 140(7). 1980–1989. 145 indexed citations
15.
16.
Dube, Anuradha, et al.. (2010). 1115 HEPATIC STEATOSIS IN PATIENTS WITH AUTOIMMUNE HEPATITIS (AIH) – PREVALENCE, PROGRESSION AND POSSIBLE SIGNIFICANCE. Journal of Hepatology. 52. S431–S431. 2 indexed citations
17.
18.
Elphick, David, et al.. (2007). Spectrum of Liver Histology in Presumed Decompensated Alcoholic Liver Disease. The American Journal of Gastroenterology. 102(4). 780–788. 43 indexed citations
19.
Sanders, David S., Simon Jones, Elaine McFarlane, et al.. (2004). Effectiveness of an upper-gastrointestinal haemorrhage unit. European Journal of Gastroenterology & Hepatology. 16(5). 487–494. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A. D’Arienzo Breakdown of academic impact, for papers by G. Cesaro Breakdown of academic impact, for papers by I. Carderi Breakdown of academic impact, for papers by D. Caroli Breakdown of academic impact, for papers by M Orsini Breakdown of academic impact, for papers by Ryoichi Narita Breakdown of academic impact, for papers by Enrico O. Souto Breakdown of academic impact, for papers by E Tavani Breakdown of academic impact, for papers by Sulleman Moreea Breakdown of academic impact, for papers by Pilar Cubiles Sánchez-Pobre
Rankless by CCL
2026